HCV franchise revenue trends
In 1Q18, AbbVie’s (ABBV) HCV (hepatitis C virus) franchise generated revenues of $919 million. That included $343 million from the US market and $576 million from international markets. The franchise had an 80% growth quarter-over-quarter.
In 1Q18, AbbVie’s anti-HCV drug Mavyret generated revenues of $850 million. It had a strong uptake in both the US and international markets. Currently, Mavyret is well-established in Japan, Spain, Germany, and Italy, along with other major markets in the world.
AbbVie anticipates revenues of $950 million from sales of its HCV products in 2Q18, with 40% of those sales from the US market. Its other HCV products include Technivie and Viekira. Its HCV franchise competes with Merck & Co.’s (MRK) Zepatier, Bristol-Myers Squibb’s (BMY) Daklinza, Gilead Sciences’ (GILD) Epclusa, and Johnson & Johnson’s (JNJ) Olysio.
Revenue trends for Kaletra and Synagis
In 1Q18, AbbVie’s Kaletra generated revenues of $73 million, which reflected a 36% decline YoY (year-over-year) and a 35% decline quarter-over-quarter. It fell 38.7% YoY on an operational basis.
In 1Q18, in the US and international markets, Kaletra generated revenues of $13 million and $60 million, respectively, which reflected a 29.3% and 37.4% YoY decline, respectively.
Kaletra treats HIV-1 (human immunodeficiency virus type 1) infection. In the anti-HIV drugs market among protease inhibitors, Kaletra’s peers include Bristol-Myers Squibb’s (BMY) Evotaz and Reyataz and Johnson & Johnson’s (JNJ) Prezista.
Synagis generated revenues of $321 million in 1Q18, which reflected a 6.9% growth YoY. The drug is used as a prophylaxis in pediatrics against serious lower respiratory tract disease caused by RSV (respiratory syncytial virus).